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Studies in vitro have demonstrated that β3-adrenergic receptors (β3-ARs) regulate protein metabolism 
in skeletal muscle by promoting protein synthesis and inhibiting protein degradation. In this study, we 
evaluated whether activation of β3-ARs by the selective agonist CL316,243 modifies the functional 
and structural properties of skeletal muscles of healthy mice. Daily injections of CL316,243 for 15 days 
resulted in a significant improvement in muscle force production, assessed by grip strength and weight 
tests, and an increased myofiber cross-sectional area, indicative of muscle hypertrophy. In addition, 
atomic force microscopy revealed a significant effect of CL316,243 on the transversal stiffness of 
isolated muscle fibers. Interestingly, the expression level of mammalian target of rapamycin (mTOR) 
downstream targets and neuronal nitric oxide synthase (NOS) was also found to be enhanced in tibialis 
anterior and soleus muscles of CL316,243 treated mice, in accordance with previous data linking  
β3-ARs to mTOR and NOS signaling pathways. In conclusion, our data suggest that CL316,243 systemic 
administration might be a novel therapeutic strategy worthy of further investigations in conditions of 
muscle wasting and weakness associated with aging and muscular diseases.
Studies in humans and animal models have revealed that β -adrenergic receptors (β -ARs) stimulation exerts 
potent anabolic effects on striated muscles1,2. Since activation of β -ARs induces skeletal muscle growth associ-
ated, in some cases, with an increase of contractile function3,4, β -AR agonists have been proposed as a therapeutic 
intervention to counteract muscle wasting correlated with aging or chronic diseases such as muscle dystrophy5–7. 
However, the potential for targeting β -ARs in dystrophies has been diminished because of the mild improve-
ments in skeletal mass/function and adverse cardiac events induced by β 1/β 2 ARs agonists2. So far, much of our 
knowledge on the role of β -AR signaling in skeletal muscle is based on studies focused on β 2-AR agonists, since 
β 2-AR is considered the predominant subtype in skeletal muscle2. However, β 3-ARs have been also identified in 
human and rodent skeletal muscles8,9. Selective activation of β 3-ARs has been established to determine impor-
tant metabolic responses in skeletal muscle such as glucose uptake, phosphorylation, and oxidation leading to an 
increase of energy expenditure10. In addition, β 3-AR agonists have been shown to affect muscle thermogenesis 
by increasing the expression of the uncoupling protein-3 (UCP-3), a protein that uncouples mitochondrial res-
piration from ATP production, thereby dissipating energy in the form of heat11. Even though metabolic effects 
of β 3-AR activation are highly recognized, less is known about the impact of β 3-ARs in the regulation of skele-
tal muscle structure and function. Using a β 3-AR selective agonist, CL316,243, we have recently demonstrated 
in vitro that β 3-ARs play a critical role in the regulation of protein metabolism in skeletal muscle12. In particu-
lar, we found that CL316,243 induced a significant increase of skeletal muscle constitutive proteins into mus-
cle cell proteins such as myosin heavy chain, myosin light chain, and actin in rat L6 myocytes. Such anabolic 
effect was associated with the activation of PI3K/Akt/mTOR pathway, via Gi/o protein, resulting in an increase 
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of p70S6 kinase (p70S6K) and protein translation. Another signaling pathway that has been linked to β 3-AR is the 
G protein inhibitory (Gi)–nitric oxide (NO) pathway13. In ventricular muscles, activation of the β 3-AR receptors 
by BRL 37344 is accompanied by decreased contractility via NO production. The β 3-AR-induced negative ino-
tropic effect was shown to be inhibited by the NOS inhibitor L-NAME and could be reversed by an excess of the 
NOS-substrate, L-arginine14.
Based on these lines of evidence, we first examined whether the in vivo administration of the β 3-AR agonist 
CL316,243 affected skeletal muscle strength in adult mice. By using atomic force microscopy (AFM), we next 
determined whether β 3-AR stimulation modifies the mechanical properties of dissociated skeletal muscle fibers. 
Furthermore, to gain more insight into the molecular mechanism underlying the β 3-AR function in skeletal 
muscle, we investigated whether CL316,243 treatment was associated with an upregulation of the putative β 3-AR 
signaling transduction pathways, involving p70S6K as well as the neuronal nitric oxide synthase (nNOS), which is 
considered the main source of NO in skeletal muscle15.
Results
CL316,243 treatment induces an increase in skeletal muscle strength in adult healthy mice. 
Muscular strength was assessed in wild-type healthy mice treated with the selective β 3-ARs agonist CL316,243 
(CL; 1 mg/kg) or saline once per day for 15 days. As shown in Fig. 1A, CL-treated mice exhibited a significant 
increase in the strength score on the weight test (23.9 ± 0.1 vs. 17.44 ± 1.23; p < 0.0001). These results were con-
firmed by the grip strength test, showing that CL316,243 treatment resulted in a 23% increase of peak force 
with respect to control (0.96 ± 0.04 vs. 0.78 ± 0.03; p = 0.008; Fig. 1B). Furthermore, we found that injections of 
CL316,243 at this dose and duration did not affect mice body weight (corresponding to 27.81 ± 0.31 grams before 
CL-treatment vs. 27.93 ± 0.30 grams after CL-treatment; t(17) = 0.275, p = 0.787).
CL316,243 regulates the mechanical properties of skeletal muscle fibers. To determine whether 
β 3-AR activation can also affect the mechanical properties of the cytoskeleton, we measured the transversal stiff-
ness of CL316,243-treated flexor digitorum brevis (FDB) fibers in the relaxed state by means of AFM-based 
nanoindentation technique. AFM is a useful tool for studying cell mechanics since it allows to apply controlled 
loads in the nanoNewtown range to living cells and measure the corresponding cell deformation with nanometer 
Figure 1. Effects of treatment with CL316,243 on muscular strength in wild type mice. (A) Mice treated 
with the β 3-AR agonist CL316,243 show an increase in the strength score. The score was calculated as the 
product of the number of links in the heaviest chain held for the full 3 sec, multiplied by the time (sec) it was 
held (n = 10 CL316,243-treated mice vs n = 9 vehicle-treated mice, unpaired t-test: t(17) = 5.495, p < 0.0001).  
(B) Grip test shows an increase in peak force in CL316,243-treated mice compared to vehicle (n = 10/9; 
unpaired t-test: t(17) = 2.978, p = 0.008). ***p < 0.0001, **p < 0.01.
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resolution16–18 (Fig. 2A and B). AFM measurements were performed on single dissociated muscle fibers incubated 
with either control solution or 1 μ M CL316,243 for 3 or 12 hours. As shown in Fig. 2C, treatment with CL316,243 
induced a significant reduction of transversal stiffness in the sub-sarcolemma region, at an indentation depth of 
200 nm, when compared to untreated fibers at both time points (p < 0.0001).
CL316,243 treatment induces an increase in muscle fiber cross-sectional area in adult healthy mice. 
To assess whether the increase in muscle strength induced by CL316,243 was associated with muscle hypertro-
phy, we measured the cross-sectional area (CSA) of hindlimb of CL-treated mice. For this purpose, we selected 
the soleus and the tibialis anterior (TA), as representative of slow-twitch and fast-twitch muscles, respectively. 
Morphometric analysis of muscle fibers revealed that CL316,243 induced a significant increase by 83% in TA 
muscle fiber CSA (p < 0.0001), whereas in soleus CSA was slightly increased by 11% (p = 0.13) compared to 
control (Fig. 3A and B). The examined muscles did not show any sign of degeneration such as intracytoplasmic 
vacuoles and centralized nuclei.
CL316,243 treatment increases the skeletal muscle expression level of p70S6K and rpS6. 
According to our previous studies in vitro, β 3-ARs stimulation up-regulates protein synthesis in myocyte cul-
tures and this effect is likely mediated by the PI3K– mTOR- p70S6K signaling pathway activation. Indeed, the 
CL316,243-induced increase of p70S6K was markedly inhibited by wortmannin, a PI3K inhibitor, and rapamycin, 
a specific inhibitor of mTOR12. Based on these observations, we examined whether the in vivo administration of 
CL316,243 modulates the expression of p70S6K and its downstream target, rpS6, in skeletal muscles obtained from 
mice treated with CL316,243 or vehicle. As shown in Fig. 4A and B, western blot analysis revealed that the expres-
sion level of phospho-p70S6K was significantly higher in both TA and soleus muscles of CL316,243-treated mice 
with respect to vehicle-treated mice (p < 0.0001). This up-regulation of p70S6K was associated with an increased 
expression of phospho-rpS6 in TA (p < 0.0001) and soleus (p < 0.05) when compared to control conditions 
(Fig. 4A and C).
CL316,243 treatment increases the skeletal muscle expression level of neuronal-NOS. Studies 
in murine myocardium have demonstrated that application of the β 3-AR agonist, BRL 37344, modulates NOS 
activity and increases NO formation19. Additional evidence for nNOS coupling to β 3-AR comes from studies show-
ing that the β 3-AR-induced negative inotropic effect is absent in cardiomyocytes of nNOS-deficient (NOS1−/−) 
mice as well as in control cardiomyocytes with acute nNOS inhibition20. We, therefore, examined whether 
CL316,243 treatment in vivo affected the expression level of nNOS, which is the most abundant NOS isoform 
in skeletal muscle. As shown in Fig. 5A and B, nNOS appeared to be regulated in both TA (p < 0.01) and soleus 
(p < 0.0001) of CL316,243-treated mice with respect to vehicle-treated mice. These data suggest that nNOS may 
be involved in the β 3-AR effects on skeletal muscle.
Discussion
This study provides the first demonstration that β 3-AR activation has important anabolic effects on skeletal muscle. 
In particular, we show that CL316,243 treatment induces a significant increase of muscle CSA and strength in 
adult healthy mice compared to controls. The increase in CSA, indicative of muscle hypertrophy, was particularly 
evident in TA compared to soleus muscle, suggesting a difference in response to β 3-agonists between fast- and 
slow-twitch skeletal muscles. The increase of CSA in TA, a muscle containing a high quantity of fast-contracting 
fibers, is in agreement with several studies reporting a hypertrophic effect of β 2-AR agonist mainly in fast-twitch 
Figure 2. Effects of CL316,243 treatment on muscle stiffness. (A) Immunofluorescence image of a dissociated 
FDB muscle fiber to visualize Z-bands (red), F-actin (green) and nuclei (blue). (B) Bright field image of a single 
FDB fiber and the AFM rectangular cantilever during nanoindentation measurements. (C) Normalized stiffness 
indicated as Young’s modulus, was obtained by AFM nanoindentation measurements from single dissociated 
muscle fibers, at 200 nm penetration depth. Fibers were incubated with CL316,243 or vehicle and stiffness was 
measured after 3 or 12 h treatment (n = 4–5 fibers/treatment, two-way ANOVA for treatment F(1,14) = 81.022, 
p < 0.0001, time F(1,14) = 0.087; p = 0.772, and treatment x time interaction F(1,14) = 1.218; p = 0.288). ***p < 0.0001. 
Calibration bar = 100 μ m.
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Figure 3. Effects of CL316,243 treatment on fiber cross-sectional area. (A) Representative images of 
hematoxylin and eosin staining of soleus (upper panels) and TA (bottom panels) muscles from mice treated 
with CL316,243 or vehicle. The stained muscle sections were analyzed for CSA. (B) Bar Graph showing the 
increase in TA CSA after treatment with CL316,243 compared to vehicle (TA CSA, n = 3–4 samples/treatment; 
unpaired t-test: t(5) = 15.08, p < 0.0001; soleus CSA n = 3 soleus muscle samples/treatment; unpaired t-test: 
t(4) = 1.86; p = 0.13). ***p < 0.0001. Calibration bar = 20 μ m.
Figure 4. Effects of CL316,243 treatment on phospho-p70S6K and phospho-rpS6 expression levels in 
skeletal muscles. (A) Representative western blot showing the p-p70S6K and p-rpS6 protein expression in 
TA and soleus skeletal muscles of mice treated with CL316,243 (CL) or vehicle (Veh). α -Tubulin was used as 
internal loading control. (B) Densitometric quantification of protein shows significant increase of of p-p70S6K 
in both soleus and TA after treatment with CL316,243 (n = 5/5; for soleus unpaired t-test: t(8) = 8.51, p < 0.0001; 
for TA unpaired t-test: t(8) = 6.04, p < 0.0001). (C) Densitometric analysis shows significant increase of p-rpS6 
p70S6K in both soleus and TA after treatment with CL316,243 (n = 5/5; for soleus unpaired t-test: t(8) = 2.93, 
p = 0.019; for TA unpaired t-test: t(8) = 5.91, p < 0.0001). *p < 0.05, ***p < 0.0001.
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fibers21,22. Conversely, there is conflicting evidence concerning whether the slow-contracting fibers are affected 
by β 2-AR agonist treatment in intact animals23. In addition, when mice were challenged with specific behavioral 
tests to evaluate skeletal muscle function, we found an increase of muscle strength in CL316,243-treated mice 
compared to vehicle-treated animals. Such positive effect was confirmed by the grip strength test, which allowed 
us to evaluate the peak resistance force, and by the weights test, evaluating the maximal isometric strength.
Several agents have been shown to increase skeletal muscle mass and force24 by regulating protein synthe-
sis, including anabolic steroids, growth hormones, IGF and β 2-AR agonists4,25–28. Most of these factors control 
the rate of protein turnover at the level of transcription, translation, degradation or a combination of these29. 
According to our previous studies in vitro, β 3-ARs stimulation up-regulates protein synthesis and this effect is 
likely due to the activation of components of the translational machinery, including the ribosomal protein S612. 
Here, the use of an in vivo model confirmed our previous in vitro data, thus providing a further demonstration 
that CL316,243 has the potential to regulate protein metabolism in skeletal muscle by increasing the expression 
of mTOR targets in the long term. The importance of mTOR in muscle size regulation has been demonstrated 
by both pharmacological and genetic studies30–32. For example, inhibition of mTOR by rapamycin prevented 
the hypertrophy of myotubes induced in vitro by IGF as well as the skeletal muscle hypertrophy in vivo induced 
by overload or clenbuterol25,33–35. A decrease in muscle mass and fiber CSA has also been revealed in mTOR 
and p70S6K knockout mice36,37. According to Navegantes and collaborators38, the anabolic effects of CL316,243 
in skeletal muscles are in part due to an inhibition of muscle proteolysis. Such anti-proteolytic effect was par-
ticularly evident in rat soleus, but not in extensor digitorum longus, suggesting a different response to β 3-ARs 
agonist of slow-twitch and fast-twitch muscle. However, the effects of β 3-AR activation in slow-twitch muscle 
fibers are quite complex since they can also involve the regulation of mitochondrial uncoupling proteins. In 
particular, immunohistochemical studies have revealed an increase of UCP-3 signals in slow-twitch muscles of 
obese mice following a chronic administration of CL316,243, which may contribute to the thermogenic effect of 
β 3-AR agonists11,39. In this study, we have also shown that CL316,243 treatment was associated with an increased 
expression of the nNOS protein in both fast- and slow-twitch muscles. In skeletal muscle, NO has been identi-
fied as a physiological intracellular messenger modulating the contractile activity of skeletal muscle, blood flow, 
exercise-induced skeletal muscle hypertrophy and glucose homeostasis40–44. The precise role of the nNOS isoform 
in skeletal muscle is still a matter of debate, although several lines of evidence suggested that NO plays a key role 
in the hypertrophic response of skeletal muscle to mechanical and metabolic stimulations45,46. NOS activity has 
been shown to promote transcription of contractile proteins, such as skeletal α -actin and type I myosin heavy 
chain mRNA, during chronic skeletal muscle overload44. According to our previous studies in vitro47, the anabolic 
Figure 5. Effects of CL316,243 treatment on nNOS expression levels in skeletal muscles. (A) Representative 
western blot showing the nNOS protein expression in TA and soleus skeletal muscles of mice treated 
with CL316,243 (CL) or vehicle (Veh). GADPH was used as internal loading control. (B) Densitometric 
quantification of protein shows significant increase of nNOS in both soleus and TA after treatment with 
CL316,243 (n = 5/5; for soleus unpaired t-test: t(8) = 8.41, p < 0.0001; for TA unpaired t-test: t(8) = 4.57, 
p = 0.002). **p < 0.01, ***p < 0.0001.
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effect of NOS might be mediated by the mTOR/p70S6K signaling pathway since NOS inhibition by L-NAME pre-
vented the activation of p70S6K in response to glucose deprivation. The importance of nNOS in skeletal muscle 
has been clearly revealed by studies carried out in nNOS-deficient (NOS1− /− ) mice48. These mice presented a 
significant reduction of muscle mass and CSA of tibialis anterior accompanied by a decrease of muscle force and 
decreased resistance to fatigue, compared with control mice. Interestingly, the TA of NOS1− /− mice showed also 
lower levels of phosphorylated rpS6, 4E-BP1, and Akt than controls, suggesting that the AKT/mTOR pathway 
activation was reduced in absence of nNOS. In addition, recent studies have demonstrated that restoration of 
NO signaling by nNOS overexpression can reduce muscle pathology in mouse models of muscular dystrophy 
(named mdx mice) by preventing muscle membrane injury and promoting regeneration49. A novel important 
finding of this study is that the acute treatment with CL316,243 induced a significant decrease of the transversal 
stiffness of single muscle fibers within the first 1000 nm of the fiber surface. This suggests that β 3-AR activation 
may modulate the elastic properties of near-membrane components, such as the external basal membrane, sar-
colemma, cytoskeletal network, and cytoplasm50. Further studies are still necessary to clarify the mechanisms by 
which CL316,243 lowers muscle stiffness and its potential role under pathological conditions associated with high 
muscle stiffness, including muscle dystrophies. Interestingly, β -adrenergic stimulation has been demonstrated to 
have also an acute effect on the myocardial stiffness of rabbits51. In particular, it has been found that exposure to 
isoprenaline, a non-selective β -AR agonist, induced a concentration-dependent reduction of myocardial stiffness 
in papillary muscles isolated from the rabbit’s ventricle. In this case, titin phosphorylation was hypothesized as 
the molecular mechanism responsible for the observed change in stiffness.
Together, these results suggest that targeting β 3-AR may be an effective therapeutic strategy for enhancing 
muscle growth and strength in a variety of disorders associated with muscle loss and degeneration.
Methods
Animals and treatment with CL316,243. C57Bl/6 J wild type male mice aged 3 months were obtained 
from a breeding colony kept at the University of Naples and University of Catania. Mice were maintained at 
a controlled temperature (21 °C ± 1 °C) and humidity (50%) on a 12 h light/dark cycle (light from 06:00 to 18:00), with 
ad libitum food and water. All animal experimentation was conducted in accordance with the guidelines laid down by 
the European Community Council (2010/63/EU). The experimental protocols have been approved by the University 
Institutional Animal Care and Use Committee from the University of Naples (#0016945, 02/16/2012). Experiments 
were performed in parallel using 2 groups of mice treated with vehicle (n = 9) or CL316,243 (n = 10) at a concentration 
of 1 mg/kg in saline by subcutaneous injections for 15 days. Two hours after the last injection, mice underwent behav-
ioral assessment of muscular strength by weights test52 and grip strength test53. Mice were then sacrificed by cervical 
dislocation and muscles were removed and frozen for western blot or processed for CSA evaluation.
Behavioral assessment of muscle strength. The weights test was performed as previously described52. 
We used a series of chain links of different weight (from 14 to 74 gr) attached to a ball of fine wire mesh. Each 
mouse was held by the tail and was allowed to grasp a series of increasing weight steel chain links placed on the 
laboratory bench. Based on the number of chain links that the mouse was able to grasp and hold for at least 3 sec-
onds, a specific score was assigned. If the mouse dropped the weight in less than 3 sec, the trial was repeated for 
3 times and the maximum time/weight achieved was considered for the final scoring. After a rest period of about 
20 sec, the next heaviest weight was tested until the mouse failed for 3 consecutive trials. A final total score was 
calculated as the product of the number of links in the heaviest chain held for the full 3 sec, multiplied by the time 
(sec) it was held. If the heaviest weight was dropped before 3 sec an appropriate intermediate value was calculated. 
For example, a mouse holding a 5-link weight for 3 seconds, but unable to lift a 6-link weight, was assigned a score 
of (5 × 3) = 15. If it held the 6-link weight for 1 second, the score was (5 × 3) + (1) = 16.
Grip strength test was performed as previously described53 by using an apparatus equipped with a mouse hori-
zontal forelimb bar (Bioseb, Model GT3). Mice were held by the tail and were allowed to grasp the horizontal bar 
with the forelimb paws. The mice were then gently pulled backward until they released the grid. The peak force 
applied by the forelimbs of the mouse was recorded in Newton (N). Each mouse received 3 test trials (with a rest 
of 2 minutes) for two consecutive sessions (1 hour apart).
Preparation and Culture of Muscle Fibers. Untreated adult mice (2–3 months old) were sacrificed by 
cervical dislocation and FDB muscles were quickly dissected and placed in a small petri dish filled with Tyrode 
Solution (in mM: 140 NaCl, 2 KCl, 2 CaCl2, 10 HEPES, and 5 glucose). FDB muscles were exposed to enzymatic 
digestion by using 0.2–0.3% Collagenase type I in Tyrode solution for 1 hour at 4 °C and then incubated in 5% 
CO2 for 1 hour at 37 °C. After three washes in Tyrode solution containing 10% FBS to block the collagenase effect 
and stabilize the fibers, FDB muscles were gently triturated to dissociate individual muscle fibers. The fibers were 
finally plated on laminin-coated culture dishes in serum-containing Tyrode solution and incubated in 5% CO2 
at 37 °C until use.
Immunofluorescence. For double immunofluorescence microscopy, the skeletal fibers in culture were 
fixed in 4% formaldehyde in PBS and permeabilized with PBS-Triton-X100 for 10 min at room temperature. 
Samples were then incubated for 4 hours with primary antibody against sarcomeric α -actinin (Sigma A-7811) 
in order to visualize Z-band on myofilaments. After washing in PBS, fibers were incubated for 1 hour in PBS 
1% BSA with TRITC-conjugated goat anti-mouse (AlexaFluor 546). We used FITC-conjugated phalloidin 
(Sigma-Aldrich; St. Louis) to stain filamentous actin (F-actin) and 4′ -6-diamidino-2-phenylindol (DAPI) for 
nuclei labeling. The specimens were visualized, with an Olympus IX-70 epifluorescence microscope equipped 
with a Hamamatzu-Orca ER II camera. Image ProPlus was used for the image acquisition.
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Atomic force microscopy. A commercial atomic force microscope (Keysight Technologies AFM model 
5500) mounted on an inverted optical microscope (Olympus IX70) was used to assess the transversal stiffness of 
single dissociated skeletal muscle fibers17,54. Silicon cantilevers with a nominal spring constant k = 0.03 N/m and 
conical tips (CSC21, MikroMasch, Germany) were used. The spring constant of each cantilever was determined 
by a thermal noise based method, which ensures a level of accuracy of 10%–15%55. To probe the mechanical 
stiffness onto and below the sarcolemma, we performed force versus distance measurements and evaluated the 
contact region of the obtained curves. The transversal stiffness was measured as the Young’s modulus calculated 
by considering an approximate purely elastic response of the indented fiber, as proposed by Oliver and collabo-
rators56. The stiffness was calculated at different penetration depths by applying controlled forces in the 0.5–2 nN 
range. Each measurement consisted of 256 force versus distance curves taken on the same 3 × 3 μ m2 region. At 
least three measurements were performed on a single fiber for each time point (3 and 12 hours) and at least three 
different fibers were probed for each treated or control condition.
Histology. Vehicle and CL316,243-treated mice were sacrificed by cervical dislocation and the limb muscles, 
TA and soleus, were harvested. Muscles were cross-cut, fixed in 10% buffered formalin, embedded in paraffin, 
then cut into 6 μ m-thick serial sections and mounted on polylysine coated slides. Sections were stained with 
Hematoxylin and Eosin staining kit (Bio-optica, Milan, Italy), according to manufacturer protocol. Microscopic 
observation was performed by Leica DM2000LED (Leica Microsystems, Wetzlar, Germany) light microscope 
equipped with Leica ICC50HD digital camera for photodocumentation. Digital images acquired were then ana-
lyzed with SigmaScan Pro 5.0 software (SYSTAT, San Jose, CA, USA) to measure CSA. Measurements were per-
formed by three independent observers and expressed as mean surface area (μ m2). A total of 300–350 muscle 
fibers were analyzed for each muscle.
Western blot analysis. TA and soleus of both vehicle and CL316,243-treated mice (n = 5 for each con-
dition) were homogenized in lysis buffer (1:2, w/v) solution containing 0.5 M β -glycerophosphate, 20 mM 
MgCl2, 10 mM ethylene glycol tetraacetic acid, and supplemented with 100 mM dithiothreitol and protease/
phosphatase inhibitors (100 mM dimethylsulphonyl fluoride, 2 mg/ml apronitin, 2 mM leupeptin, and 10 mM 
Na3VO4). Protein concentration was determined by the Bio-Rad protein assay (Bio-Rad, Milan, Italy). Samples 
containing 100 μ g of proteins were denatured, separated on a 10% (for p70S6K and rpS6) or 8% (for nNOS) 
SDS-polyacrylamide gel, and electro-transferred onto a nitrocellulose membrane using a Bio-Rad Trans-Blot 
(Bio-Rad, Italy). Western blotting detection reagents were obtained from Amersham Biosciences (UK); the 
nitrocellulose membrane was from Hybond ECL (GE Healthcare, UK). Proteins were visualized by reversible 
staining with Ponceau S solution and destained in PBS57. Membranes were blocked at room temperature in 
milk buffer (1Χ PBS, 5–10% v/v non-fat dry milk, 0.2% v/v Tween-20) and then incubated at 4 °C overnight 
with the following primary antibodies: anti-phospho-p70S6K (1:1000; Cell Signaling Technology, Massachusetts, 
USA), anti-phospho-rpS6 (1:1000; Cell Signaling Technology, Massachusetts, USA), anti-nNOS (1:300; Santa 
Cruz, California, USA); anti-α -tubulin antibody (1:1000; Cell Signaling Technology, Massachusetts, USA) or 
anti-GAPDH (1:8000; Sigma Aldrich, Milan, Italy). The membranes were then incubated for 90 min at room 
temperature with 1:5000 horseradish peroxidase-conjugated secondary anti-rabbit or anti-mouse antibodies. The 
resulting complexes were visualized using chemiluminescence Western blotting detection reagents. The western 
blot images were scanned using GS-800 imaging densitometer (Bio-Rad, Italy) and analyzed using Quantity One 
software (Biorad, Italy). The background-subtracted density of the bands in all blots was measured and normal-
ized using α -tubulin or GAPDH.
Statistical analysis. Data are presented as mean ± standard error of the mean (SEM). Statistical analy-
ses were performed by using Systat software (Chicago, IL, USA). To compare the experimental conditions, we 
used unpaired Student’s t-test. A single TA and soleus muscle were examined for each treated animal. Two-way 
ANOVA was used for the AFM data. The level of significance was set at p < 0.05.
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